Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Book a demo
Recordati logo — An international leader in pharmaceuticals, committed to inn...

Recordati

An international leader in pharmaceuticals, committed to innovation and excellence since 1926.

Founded 1926 1001-5000 employees Biotechnology, Health Care +1

General Information

Company Name Recordati
Founded Year 1926
Employees 1001-5000
Industries Biotechnology, Health Care, Manufacturing
Social

BounceWatch is an independent company data service, not affiliated with Recordati. To contact Recordati, visit recordati.it.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Recordati compare?

A PDF of Recordati and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Recordati soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About Recordati

Recordati is an internationally recognized pharmaceutical group that has been committed to innovation and excellence since 1926. With a workforce exceeding 3,300 employees, the company focuses on the research, development, manufacturing, and marketing of pharmaceuticals. Headquartered in Milan, Italy, Recordati operates across major European countries, Russia, various Central and Eastern European nations, Turkey, and the United States. The company boasts a sales force of over 1,700 medical representatives who promote a diverse array of innovative pharmaceuticals, both proprietary and licensed, across multiple therapeutic areas, including a specialized division for rare disease treatments. In 2012, Recordati achieved consolidated revenue of €828.3 million, an operating income of €167.0 million, and a net income of €118.5 million. Recordati is a preferred partner for new product licenses in its designated territories. The organization is committed to developing new drug entities in cardiovascular and urogenital therapeutic areas and treatments for rare diseases. The company has last received funding in December 2018. With its long-standing history and focus on innovation, Recordati presents a strong investment opportunity in the biotechnology, health care, and manufacturing industries.

Business keywords: Pharmaceuticals, Innovation, Research and Development, Rare Diseases, Global Operations, Publicly Traded, Medical Representatives, Cardiovascular Therapeutics, Urogenital Therapeutics, European Market, American Market, Commercialization and Licensing, Chemicals, Industrial Operations

Funding Rounds & Investors (1)

View All
Funding Stage Amount Investors Lead Investors Date
Funding Round Undisclosed -
01 Dec 2018

Recordati Alternatives & Competitors

View All Alternatives
Recordati vs
Dicerna Pharmaceuticals
Dicerna Pharmaceuticals

Pioneering breakthroughs in genetic disorders and liver diseases using RNA interference technology.

Post-IPO Equity
201-500 employees
Biotechnology, Health Care
Recordati vs
Xcene Research
Xcene Research Nigeria

Finding Innovative Global Health Solutions For Today and Tomorrow Through Clinical Research. # Organ...

110 employees
Biotechnology, Health Care
Recordati vs
IXALTIS SA
IXALTIS SA France

DEVELOPING INNOVATIVE TREATMENTS FOR GENITOURINARY TRACT DISORDERS

Venture round
2 employees
Biopharma, Biotechnology
View all alternatives

FAQ About Recordati

An international leader in pharmaceuticals, committed to innovation and excellence since 1926.
Recordati was founded in 1926.
Recordati operates in Biotechnology, Health Care and Manufacturing. Its work centres on Pharmaceuticals, Innovation, Research and Development and Rare Diseases.
Recordati has approximately 1001-5000 employees.
Recordati has completed 1 funding round.
Top alternatives and competitors to Recordati include Dicerna Pharmaceuticals, Xcene Research, IXALTIS SA, Micar Innovation (Micar21), VALEAS SPA INDUSTRIA CHIMICA E FARMACEUTICA. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Recordati and Dicerna Pharmaceuticals are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Recordati, https://bouncewatch.com/company/recordati, updated 9 November 2024. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Book a demo 30 minutes